Tyme Technologies Inc (TYME)

Currency in USD
0.3107
0.0000(0.00%)
Real-time Data·
Showing Tyme Tech historical data. For real-time data please try another search
Fair Value
Day's Range
0.28500.3150
52 wk Range
0.28500.3150
Key Statistics
Prev. Close
0.2875
Open
0.2901
Day's Range
0.285-0.315
52 wk Range
0.285-0.314
Volume
-
Average Volume (3m)
1.34M
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TYME Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Tyme Technologies Inc Company Profile

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.

Compare TYME to Peers and Sector

Metrics to compare
TYME
Peers
Sector
Relationship
P/E Ratio
UnlockNaNNaNUnlock
PEG Ratio
UnlockNaNNaNUnlock
Price/Book
UnlockNaNNaNUnlock
Price / LTM Sales
UnlockNaNNaNUnlock
Upside (Analyst Target)
UnlockNaNNaNUnlock
Fair Value Upside
UnlockNaNNaNUnlock

Earnings

Latest Release
Nov 07, 2022
EPS / Forecast
-- / -0.06
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TYME Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.